Centessa Pharmaceuticals plc
CNTA
$39.60
-$0.02-0.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.54% | -9.03% | -92.63% | 76.52% | -161.54% |
| Total Depreciation and Amortization | -251.48% | 4.87% | 4.15% | 158.65% | -256.78% |
| Total Amortization of Deferred Charges | 224.35% | -7.51% | -6.09% | -48.00% | -- |
| Total Other Non-Cash Items | 17.46% | -17.79% | 31.28% | -84.24% | 384.15% |
| Change in Net Operating Assets | 110.83% | -161.05% | 148.00% | -252.67% | 109.21% |
| Cash from Operations | 4.30% | -159.72% | 60.78% | -33.75% | -100.10% |
| Capital Expenditure | 95.30% | -85.71% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -450.80% | 256.12% | 82.09% | -989.55% | -44.44% |
| Cash from Investing | -452.14% | 255.04% | 82.03% | -989.55% | -44.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7,861.29% | 108.91% | -78.34% | 48.19% | -97.85% |
| Repurchase of Common Stock | -40.80% | 97.22% | -- | -- | -63.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | 191.73% | -- | -- |
| Cash from Financing | 8,145.56% | 114.14% | -47.99% | 4.15% | -98.80% |
| Foreign Exchange rate Adjustments | 435.93% | -343.36% | 92.55% | -150.03% | 259.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.61% | 110.78% | 78.09% | -2,255.48% | -104.41% |